Original Article
Viral Load and Disease Progression in Infants Infected with Human Immunodeficiency Virus Type 1
N Engl J Med 1997; 336:1337-1342May 8, 1997
- Abstract
Background
There are only limited data on human immunodeficiency virus type 1 (HIV-1) RNA in perinatally infected infants. Understanding the dynamics of HIV-1 infection and its relation to disease progression may help identify opportunities for effective antiviral treatment in infected infants.
Methods
We obtained plasma samples from 106 HIV-infected infants at birth; at 1, 2, 4, 6, 9, 12, 15, and 18 months of age; and subsequently every 6 months. HIV-1 RNA was assayed by means of a reverse-transcription polymerase chain reaction. The infants were born between 1990 and 1993, and only 21 percent of the infants' mothers received any treatment with zidovudine during pregnancy.
Results
Plasma HIV-1 RNA levels increased rapidly after birth, peaked at 1 to 2 months of age (median values at 1 and 2 months, 318,000 and 256,000 copies per milliliter, respectively), and then slowly declined to a median of 34,000 copies per milliliter at 24 months. Newborns with a first positive HIV-1 culture within 48 hours after birth had significantly higher HIV-1 RNA levels, although only during the first two months of life, than those with a first positive culture seven or more days after birth. Infants with a rapid progression of disease had higher peak HIV-1 RNA levels in the first two months of life than those without rapid progression (median value, 724,000 vs. 219,000 copies per milliliter; P = 0.006), as well as a higher geometric mean value during the first year of life (median value, 330,000 vs. 158,000 copies per milliliter; P = 0.001).
Conclusions
In perinatally infected infants, HIV-1 RNA levels are high and decline only slowly during the first two years of life. Infants with very high viral loads in the first months of life are at increased risk for a rapid progression of disease, which suggests that early treatment with antiretroviral agents may be indicated for these infants.
Media in This Article
Figure 4
Kaplan–Meier Estimates of the Probability of Disease Progression, According to the Median Number of HIV-1 RNA Copies during the First Two Months of Life.Figure 1
Plasma HIV-1 RNA in Multiple Samples from 106 Infants with HIV-1, According to Age.Article Activity
- Article
In perinatally acquired human immunodeficiency virus type 1 (HIV-1) infection, it is possible to make precise estimates of the time of infection and observe the subsequent changes in plasma viremia. Measurement of the viral load may be of considerable importance not only in understanding the pathogenesis of HIV-1 infection in infants and children but also in managing the infection.
The level of the plasma HIV-1 load appears to predict the progression of disease in children,1-8 but studies of children have been limited. There is now considerable evidence that in adults the plasma HIV-1 RNA load can be used to predict the progression of disease and is useful in assessing antiretroviral therapies.9-12 The plasma HIV-1 RNA level in adults reaches a steady state within 6 to 12 months after the initial infection; however, in many adults, the RNA level has already reached a steady state at the time of the initial diagnosis.13
We used prospective data from the Women and Infants Transmission Study (WITS) to examine the relation between the viral load and the clinical outcome in infants and children with HIV-1 infection. The results of such analyses should help clinicians decide when to administer antiretroviral therapies.
Methods
Patient Population
WITS is a multicenter, longitudinal study of the natural history of HIV-1 infection in pregnant women and their infants. The enrollment of participants began in 1989. At present, pregnant women infected with HIV-1 and their infants are recruited for enrollment at study centers in Massachusetts (Boston and Worcester), Illinois (Chicago), New York (two centers in New York City), Texas (Houston), and Puerto Rico (San Juan). According to the study protocol, no attempt is made to control the use of antiviral treatment in mothers or infants. All mothers are advised not to breast-feed their infants. Since March 1994, pregnant women have been counseled about the use of zidovudine to prevent the transmission of HIV to their infants.
For the present analysis, the population consisted of perinatally infected singleton infants born to HIV-1–positive mothers between January 8, 1990, and December 3, 1993. Plasma HIV-1 RNA levels were measured in 106 of these infants, with a total of 673 samples available for analysis. At the time of plasma-sample selection, all 106 infants had at least 12 months of follow-up or had died before 12 months of age.
The study period predated the completion of AIDS Clinical Trials Group (ACTG) protocol 076, which showed that the administration of zidovudine to HIV-infected women during pregnancy and labor and to their infants during the first six weeks of life resulted in a significantly decreased risk of HIV transmission. Thus, only 22 mothers (21 percent) in our study received zidovudine during pregnancy, and it was administered primarily as treatment for the mothers.
Sample Collection and Definitions
Blood specimens were collected between February 1990 and July 1995. Whole blood was collected by venipuncture in Vacutainer tubes containing heparin. Peripheral-blood specimens were routinely collected during the first 7 days of life (one specimen); at 1, 2, 4, 6, 9, 12, and 18 months of age; and every 6 months thereafter. In addition, specimens were obtained from some infants at 15 months of age.
The infection status of each infant was determined according to a working definition of HIV-1 infection.14,15 A child was considered to be infected if peripheral-blood mononuclear-cell cultures for HIV-1 were positive at two or more visits.
Early (in utero) infection was defined as a positive HIV-1 culture in the first 48 hours of life. Late (intrapartum) infection was defined as at least one negative but no positive cultures during the first seven days of life and positive cultures thereafter (modified from Bryson et al.16 ).
Rapid progression of disease was defined as a class C clinical event, according to the Centers for Disease Control and Prevention's (CDC's) 1994 revised classification system for HIV infection in children,17 or death by 18 months of age. Nonrapid progression of disease was defined as the absence of these end points by 18 months.
Laboratory Analysis
Heparinized blood samples were transported to the local laboratory, and the peripheral-blood mononuclear cells were separated with Ficoll–Hypaque centrifugation and subsequently cultured for HIV-1. The remaining plasma was centrifuged, divided into aliquots, and stored at -70°C. The recommended time from collection to freezing at -70°C was less than six hours. The HIV-1 serologic status of the mothers was determined with the use of a commercially available enzyme-linked immunosorbent assay and confirmed with the Western blot assay.
Qualitative peripheral-blood mononuclear-cell cultures and quantitative peripheral-blood mononuclear-cell microcultures were performed according to the ACTG consensus protocol, with standard modifications for samples from children, and all laboratories participated in the ACTG quality-control program.14,18
Plasma HIV-1 RNA was measured in two laboratories according to ACTG quality-assurance recommendations. The quantitative HIV-1 RNA polymerase chain reaction (PCR) was performed with an HIV-1 assay according to the manufacturer's instructions (Amplicor HIV-1 Monitor Test, Roche Diagnostic Systems, Branchburg, N.J.). RNA was extracted from heparinized samples with the use of a modification of the method of Boom et al.19 The use of silica to extract RNA from heparinized plasma has been found to give results similar to those with the recommended use of EDTA-treated plasma.20 Briefly, plasma samples (200 μl) were added to 0.90 ml of lysis buffer containing guanidinium thiocyanate, an internal quantitation standard, and silica particles. After a short incubation, the silica particles and bound nucleic acid were concentrated by centrifugation and washed twice with a buffer containing guanidinium thiocyanate, twice with 70 percent ethanol, and once with acetone. A low-ionic-strength diluent (400 μl) was added to the dried silica to elute bound nucleic acid.
Fifty microliters of each prepared RNA sample was used for the PCR assay. After amplification and detection of the PCR product, the initial HIV-1 RNA load in each sample was calculated by comparing it with the internal quantitation standard, and the results were expressed as HIV-1 RNA copies per milliliter of plasma. Samples in which HIV-1 RNA was not detected were assigned a value of 400 HIV-1 RNA copies per milliliter for the purpose of the statistical analysis.
Statistical Analysis
The HIV-1 RNA load was analyzed on a logarithmic (base 10) scale, with the results converted to copies per milliliter. The mean or average number of copies is actually a geometric mean. Three summary measures were used to characterize the pattern of the HIV-1 RNA load during the first year of life. The early peak was defined as the maximal value during the period from birth to two months of age, among infants with at least one available measurement at one or two months of age. The average viral burden and the slope of the decline in the viral burden between months 1 and 12 were calculated from all available values during this period, among infants with at least two available values. The within-person slopes were calculated by least-squares regression. Ninety-five percent confidence intervals were calculated for median values.21 Two-sample comparisons of viral load were made with the Mann–Whitney–Wilcoxon test.22 The cumulative probabilities of a rapid progression of disease by certain ages were calculated by the Kaplan–Meier method and compared with the use of the log-rank test.23,24 All P values are two-sided.
Results
HIV-1 RNA was measured in a total of 673 plasma samples from 106 HIV-infected infants (born by December 3, 1993), with a mean of 6.35 samples per infant. Most of the specimens (92 percent) were acquired before 30 months of age.
Data from study visits before December 1, 1995, were analyzed. On the basis of these data, 140 children were classified as infected with HIV-1. The mothers of the 106 children included in the study did not differ significantly from the mothers of the 34 excluded infants, with respect to race or ethnic group, age at delivery, education, results of HIV-1 cultures during pregnancy and at delivery, use of hard drugs (heroin, cocaine, methadone, or injection drugs) during pregnancy, duration of rupture of membranes, percentage of CD4+ cells, infant's gestational age, and mode of delivery. However, more mothers of excluded infants used zidovudine according to the ACTG 076 protocol (47 percent, vs. 2 percent of the mothers whose infants were included; P<0.001), reflecting the fact that most of the excluded infants were born after the results of trial ACTG 076 were made public.
The infants included in the study did not differ significantly from those who were excluded, with respect to the results of HIV-1 cultures at birth, 48 hours, and seven days; the percentage of CD4+ cells at birth, one month, and one year; birth weight; or sex. However, the infants included in the study differed from those not included in terms of the study site (P = 0.03) and receipt or nonreceipt of zidovudine according to the ACTG 076 regimen (P<0.001). Sixty-six percent of the cohort received therapeutic zidovudine (not the ACTG 076 regimen) sometime during the study. However, most analyses and conclusions rely primarily on samples obtained before the use of zidovudine (94 percent of the samples obtained during the first two months and 74 percent of those obtained during the first year).
Plasma HIV-1 RNA Load in Infants
There was a wide range of plasma HIV-1 RNA values in the 106 infected children at all time points (Figure 1Figure 1
Plasma HIV-1 RNA in Multiple Samples from 106 Infants with HIV-1, According to Age.). The median RNA load was below the cutoff level at birth (<400); rose rapidly to 318,000 and 256,000 copies per milliliter at 1 and 2 months, respectively; and gradually declined to 34,000 copies per milliliter (approximately a decrease of 1 in the log10 of the number of copies per milliliter) by 24 months of age. When samples obtained after the administration of zidovudine were excluded from the analysis, the pattern was quite similar.Since the predominant pattern was a rapid rise in the viral load followed by a slow decline, we examined three summary measures to characterize this pattern: the early peak value (from birth to 2 months), the average viral burden in each infant during months 1 through 12, and the slope of the decline during months 1 through 12 (Table 1Table 1
Median HIV-1 RNA Levels in 106 Infants with HIV-1 Infection.). The median early peak value was 299,000 RNA copies per milliliter; the median value for the average viral burden was 185,000 copies per milliliter, and the slope was -0.048 log10 copies per milliliter per month (Table 1).On the basis of the WITS definition of infection status, it was possible to estimate the sensitivity of the HIV-1 RNA PCR assay by determining the number of plasma specimens with detectable RNA. The sensitivity was 34 percent (13 of 38 specimens) at birth and ranged from 95 to 99 percent at one, two, four, and six months.
Viral Load in Relation to Early or Late Infection
Infants with early HIV-1 infection (in utero transmission) and those with late infection (peripartum transmission) had significantly different median HIV-1 RNA values in the early months of life. At birth, the median HIV-1 RNA values were 10,800 copies per milliliter in the early-infection group and less than 400 copies per milliliter in the late-infection group (P = 0.002), and at one month, the median values were 716,000 and 100,000 copies per milliliter, respectively (P = 0.02). The median peak values were 780,000 copies per milliliter in the early-infection group and 243,000 copies per milliliter in the late-infection group (P = 0.04) (Table 1). After 1 month, the median RNA values in the two groups were similar, and in both groups, the values slowly declined over a period of 24 months to 101,000 and 28,900 copies per milliliter (P = 0.54). The average viral burden and the slope of the decline during the first year were similar in the infants with early infection and those with late infection.
Viral Load in Relation to Disease Progression
HIV-1 RNA levels were compared in the group of children with rapid progression of disease (CDC class C HIV-1 disease or death by 18 months of age) and in the group without rapid progression (Figure 2Figure 2
Median HIV-1 RNA Levels According to Whether the Infants Had Rapid or Nonrapid Progression of Disease.). From birth to 24 months of age, the children with rapid progression had a higher median HIV-1 RNA load than those without rapid progression. This difference was significant at 1 month (431,000 vs. 105,000 HIV-1 RNA copies per milliliter, P =0.01), 2 months (490,000 vs. 236,000, P = 0.03), 6 months (377,000 vs. 185,000, P = 0.04), 9 months (456,000 vs. 128,000, P = 0.003), 15 months (277,000 vs. 70,900, P = 0.03), 18 months (130,000 vs. 45,900, P = 0.01), and 24 months (233,000 vs. 27,500, P = 0.006). The corresponding early peak values were 724,000 copies per milliliter in the group with rapid progression and 219,000 copies per milliliter in the group without rapid progression (P =0.006), and the average viral loads were 330,000 and 158,000 copies per milliliter, respectively (P = 0.001) (Table 1).To highlight the range of the data around the median HIV-1 RNA load in infants with rapid progression and those with nonrapid progression, individual data points at birth and one, two, and four months are shown in Figure 3Figure 3
HIV-1 RNA Levels during the First Four Months of Life in the Infants with Rapid Progression of Disease (Solid Circles) and Those with Nonrapid Progression (Open Circles).. At each age and especially at birth, there is considerable overlap in the values for the two groups. No threshold RNA value was identified that could predict rapid progression to advanced HIV-1 disease or death. However, no infant with an HIV-1 RNA value below 70,000 to 80,000 copies per milliliter at one, two, and four months of age had rapidly progressive disease.Early peak HIV-1 RNA values were analyzed with the use of a Kaplan–Meier plot depicting the cumulative incidence of CDC class C HIV-1 disease or death over time. Children were classified according to whether the early peak RNA load was above or below the median value. Figure 4Figure 4
Kaplan–Meier Estimates of the Probability of Disease Progression, According to the Median Number of HIV-1 RNA Copies during the First Two Months of Life. shows a striking difference between these two groups, with an early peak value above the median associated with a 44 percent rate of progression by 24 months and a value below the median associated with a 15 percent rate of progression (P = 0.008).Discussion
This prospective study of the plasma HIV-1 RNA load in infected infants reveals a unique pattern of HIV-1 replication and plasma viral levels. The mean HIV-1 RNA load rises from generally low values (<10,000 copies per milliliter) at birth to extremely high values (>100,000 copies per milliliter) within the first 2 months of life and falls very slowly until at least the age of 24 months.
The generally low HIV-1 RNA levels at birth suggest that most neonates have acquired their infections very close to the time of birth, probably in the intrapartum period, or that maternal or placental factors inhibit viral replication before delivery. The rapid rise in the HIV-1 RNA load within one to two months, to values of several hundred thousand copies per milliliter, reflects a rapid replication of the virus within a short period of time, but the subsequent decline suggests a process of containment, possibly immune in nature, which prevents a further rise in the viral load. The slow decline in the viral load, which contrasts sharply with the rapid decline after primary HIV-1 infection in adults,13 suggests that the still immature neonatal immune system has difficulty containing the viral infection. The similarity in the general pattern of plasma and serum HIV-1 RNA loads in children, as measured in smaller prospective studies1,8 and cross-sectional studies,2-7,25 is striking. Although the studies of HIV-1 RNA in children are much smaller than those in adults, the collective HIV-1 RNA data in children clearly indicate a unique pattern of viral replication and containment.
In our study, the RNA load differed according to whether the infection was acquired early or late. Infants with positive HIV-1 cultures during the first 48 hours after birth had significantly higher HIV-1 RNA values than those whose cultures were negative during the first seven days. However, the median HIV-1 RNA plasma level in the early-infection group was only 10,800 copies per milliliter at birth. This low value may indicate the presence of a maternal or placental protective mechanism that has not yet been identified. An alternative explanation may be that the infants were infected just before birth. The differences between the early-infection and late-infection groups disappeared very shortly after birth, and the subsequent response to the virus was similar in the two groups.
Although it is difficult to evaluate the effect of zidovudine on the viral load in this observational study, treatment did not have a pronounced effect on the results of the analysis. The pattern of the viral load over time changed very little when the plasma samples obtained after the receipt of therapeutic zidovudine were excluded from the analysis. Most of the samples were obtained before the receipt of therapeutic zidovudine.
The infants whose disease progressed rapidly tended to have high numbers of HIV-1 RNA copies not only at birth but also during most of the first 24 months of life. Although the differences between the median HIV-1 RNA levels in the rapid-progression group and the median levels in the nonrapid-progression group are large, there was considerable overlap in the values between the two groups. There was no threshold value above which rapid progression of HIV-1 disease could be predicted. However, none of the infants with less than 70,000 copies per milliliter at one, two, and four months had rapidly progressive disease. Additional studies are needed to verify this finding.
In summary, in this prospective study of 106 children with HIV-1 infection, there was a rapid rise in the median HIV-1 RNA load in the first 1 or 2 months after birth, followed by a slow decline during the next 22 months. This same pattern was observed in infants with early infection and those with late infection and in infants with a rapid progression of disease and those with a nonrapid progression. The association of rapidly progressive disease with a higher plasma HIV-1 RNA load in the first months of life suggests that early antiretroviral treatment should be of some use in this subgroup of children. We found no threshold viral level above which HIV disease progressed rapidly, but there may be a threshold level below which rapid progression does not occur.
We are indebted to the investigators, the study staffs, and especially the families who have participated in the Women and Infants Transmission Study and to Roche Molecular Systems for providing the Amplicor HIV-1 Monitor Test kits.
Source Information
From the Department of Pediatrics, Section of Allergy and Immunology, Baylor College of Medicine, Houston (W.T.S.); Johns Hopkins University, Baltimore (T.C.Q.); the National Institute of Allergy and Infectious Diseases, Bethesda, Md. (T.C.Q., J.F.L.); the Virology Department, Columbia–Presbyterian Hospital, New York (P.L.); the National Institute of Child Health and Human Development, Bethesda, Md. (L.M.); the New England Research Institutes, Watertown, Mass. (S.A., L.A.K.); the University of Illinois at Chicago, Chicago (K.R.); the State University of New York Health Science Center at Brooklyn, Brooklyn (E.H.); the University of Puerto Rico, San Juan (C.D.); the Department of Biostatistics, Harvard School of Public Health, Boston (M.P.); and the National Institute on Drug Abuse, Rockville, Md. (V.S.).
Address reprint requests to Dr. Shearer at Texas Children's Hospital, 6621 Fannin St., MC 1-3291, Houston, TX 77030.
The members of the Women and Infants Transmission Study Group are listed in the Appendix.
Appendix
The Women and Infants Transmission Study Group included the following investigators and centers (with grants from the National Institutes of Health listed in parentheses): W. Shearer, C. Hanson, and N. Cooper — Baylor College of Medicine, Houston (U01 AI 34840, AI 36211, and RR 00188); J. Pitt and A. Higgins — Columbia–Presbyterian Hospital, New York (U01 AI 34842); K. Rich and D. Turpin — University of Illinois at Chicago (U01 AI 34841); S. Landesman, H. Mendez, and G. Moroso — State University of New York, Brooklyn (HD-8-2913 and R0-1-HD-25714); R. Tuomala, E. Cooper, and D. Mesthene — Brigham and Women's Hospital, Boston (U01 AI 34856); C. Diaz and E. Pacheco-Acosta — University of Puerto Rico, San Juan (U01 AI 34858); M.G. Fowler, J. Lew, and E. Matzen — National Institute of Allergy and Infectious Diseases, Bethesda, Md.; A. Willoughby, D. Burns, J. Moye, J. Read, and L. Mofenson — National Institute of Child Health and Human Development, Bethesda, Md.; V. Smeriglio and K. Davenny — National Institute on Drug Abuse, Rockville, Md.; and S. McKinlay, L. Kalish, and K. Sherrieb — New England Research Institutes, Watertown, Mass. (N01 AI 05072 and N01 AI 35161).
- References
References
1
De Rossi A ,Masiero S ,Giaquinto C , et al. Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest 1996;97:323-330
CrossRef | Web of Science | Medline2
Palumbo PE ,Kwok S ,Waters S , et al. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr 1995;126:592-595
CrossRef | Web of Science | Medline3
O'Brien TR ,Blattner WA ,Waters D , et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996;276:105-110
CrossRef | Web of Science | Medline4
McIntosh K ,Shevitz A ,Zaknun D , et al. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 1996;15:1087-1091
CrossRef | Web of Science | Medline5
Mofenson LM, Korelitz J, Meyer WA III, et al. The relationship between serum HIV-1 RNA levels, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis (in press).
6
Dickover R, Kwok S, Wei L, Christopherson C, Bryson Y. HIV RNA peak during primary viremia is a major determinant of clinical course in perinatally infected infants. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28–February 1, 1996. Alexandria, Va.: Infectious Diseases Society of America, 1996:93. abstract.
7
Tetali S, Romano J, Than S, et al. Virus load as marker of disease progression in HIV-infected children. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28–February 1, 1996. Alexandria, Va.: Infectious Diseases Society of America, 1996:99. abstract.
8
Abrams EJ, Weedon JC, Lambert G, Steketee R. HIV viral load early in life as a predictor of disease progression in HIV-infected infants. In: Vol. 2. Abstracts. XI International Conference on AIDS, Vancouver, B.C., July 7–12, 1996:25. abstract.
9
Mellors JW ,Rinaldo CR Jr ,Gupta P ,White RM ,Todd JA ,Kingsley LA . Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170
CrossRef | Web of Science | Medline10
Mellors JW ,Kingsley LA ,Rinaldo CR Jr , et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-579
Web of Science | Medline11
Jurriaans S ,Van Gemen B ,Weverling GJ , et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994;204:223-233
CrossRef | Web of Science | Medline12
Henrard DR ,Phillips JF ,Muenz LR , et al. Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-558
CrossRef | Web of Science | Medline13
Ho DD . Viral counts in HIV infection. Science 1996;272:1124-1125
CrossRef | Web of Science | Medline14
Hollinger FB ,Bremer JW ,Myers LE ,Gold JWM ,McQuay L , NIH/NIAID/DAIDS/ACTG Virology Laboratories. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992;30:1787-1794
Web of Science | Medline15
Landesman SH ,Kalish LA ,Burns DN , et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996;334:1617-1623
Full Text | Web of Science | Medline16
Bryson YJ ,Luzuriaga K ,Sullivan JL ,Wara DW . Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992;327:1246-1247
Full Text | Web of Science | Medline17
1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of ageMMWR Morb Mortal Wkly Rep 1994;43:1-10
Medline18
McIntosh K ,Pitt J ,Brambilla D , et al. Blood culture in the first 6 months of life for the diagnosis of vertically transmitted human immunodeficiency virus infection. J Infect Dis 1994;170:996-1000
CrossRef | Web of Science | Medline19
Boom R ,Sol CJ ,Salimans MM ,Jansen CL ,Wertheim-van Dillen PM ,van der Noordaa J . Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503
Web of Science | Medline20
Dickover RE ,Garratty EM ,Herman SA , et al. Identification of levelsof maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605
CrossRef | Web of Science | Medline21
Zar JH. Biostatistical analysis. 2nd ed. Englewood Cliffs, N.J.: Prentice-Hall, 1974:390.
22
Rosner B. Fundamentals of biostatistics. 3rd ed. Boston: PWS-Kent Publishing, 1990:304-9.
23
Kaplan E ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science24
Peto R ,Peto J . Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972;135:185-206
CrossRef | Web of Science25
Conway B, Allen U, Lapointe N, et al. HIV viremia in relation to clinical and laboratory correlates among HIV-infected children. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28–February 1, 1996. Alexandria, Va.:Infectious Diseases Society of America, 1996:102. abstract.
- Citing Articles (177)
Citing Articles
1
Jeanne A. Jordan, Christine O. Ibe, Miranda S. Moore, Christel Host, Gary L. Simon. (2012) Evaluation of a manual DNA extraction protocol and an isothermal amplification assay for detecting HIV-1 DNA from dried blood spots for use in resource-limited settings. Journal of Clinical Virology
CrossRef2
Jean Maritz, Wolfgang Preiser, Gert U. van Zyl. (2011) Establishing diagnostic cut-off criteria for the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative test through validation against the Amplicor DNA test v1.5 for infant diagnosis using dried blood spots. Journal of Clinical Virology
CrossRef3
B. G. Kapogiannis, M. M. Soe, S. R. Nesheim, E. J. Abrams, R. J. Carter, J. Farley, P. Palumbo, L. J. Koenig, M. Bulterys. (2011) Mortality Trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Clinical Infectious Diseases 53:10, 1024-1034
CrossRef4
Raphael W. Lihana, Raphael M. Lwembe, Xiuqiong Bi, Washingtone Ochieng, Annie Panikulam, Tresa Palakudy, Rachel Musoke, Mary Owens, Azumi Ishizaki, Frederick A. Okoth, Elijah M. Songok, Hiroshi Ichimura. (2011) Efficient monitoring of HIV-1 vertically infected children in Kenya on first-line antiretroviral therapy. Journal of Clinical Virology 52:2, 123-128
CrossRef5
Andrew Prendergast, Maria O'Callaghan, Esse Menson, Djamel Hamadache, Sam Walters, Nigel Klein, Philip Goulder. (2011) Factors Influencing T Cell Activation and Programmed Death 1 Expression in HIV-Infected Children. AIDS Research and Human Retroviruses110907085619009
CrossRef6
Céline Nguefeu Nkenfou, Elise Elong Lobé, Odile Ouwe-Missi-Oukem-Boyer, Martin Samuel Sosso, Béatrice Dambaya, Luc-Christian Gwom, Suzie Tetang Moyo, Charlotte Tangimpundu, Georgia Ambada, Nadine Fainguem, Irenée Domkam, Etienne Nnomzo'o, Daniel Ekoa, Pascal Milenge, Vittorio Colizzi, Pierre Joseph Fouda, Giulia Cappelli, Judith Ndongo Torimiro, Anne Cécile Zoung-Kanyi Bissek. (2011) Implementation of HIV Early Infant Diagnosis and HIV Type 1 RNA Viral Load Determination on Dried Blood Spots in Cameroon: Challenges and Propositions. AIDS Research and Human Retroviruses110727133926003
CrossRef7
Joana Paixao Monteiro-Cunha, Adriano Fernando Araujo, Edson Santos, Bernardo Galvao-Castro, Luiz Carlos Junior Alcantara. (2011) Lack of High-Level Resistance Mutations in HIV Type 1 BF Recombinant Strains Circulating in Northeast Brazil. AIDS Research and Human Retroviruses 27:6, 623-631
CrossRef8
Bongeka Nqoko, Cheryl L. Day, Nazma Mansoor, Marwou De Kock, E. Jane Hughes, Tony Hawkridge, Gilla Kaplan, W. Henry Boom, Gregory D. Hussey, Willem A. Hanekom. (2011) HIV-Specific Gag Responses in Early Infancy Correlate with Clinical Outcome and Inversely with Viral Load. AIDS Research and Human Retroviruses110512192649019
CrossRef9
François Rouet, Florian Liégeois, Augustin Mouinga-Ondémé, Dramane Kania, Johannes Viljoen, Sammy Wambua, Nicole Ngo-Giang-Huong, Hervé Ménan, Martine Peeters, Eric Nerrienet. (2011) Current challenges to viral load testing in the context of emerging genetic diversity of HIV-1. Expert Opinion on Medical Diagnostics 5:3, 183-202
CrossRef10
Andrea L Ciaranello, Ji-Eun Park, Lynn Ramirez-Avila, Kenneth A Freedberg, Rochelle P Walensky, Valeriane Leroy. (2011) Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Medicine 9:1, 59
CrossRef11
Avinash K. Shetty, Yvonne A. Maldonado. 2011. Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in the Infant. , 622-660.
CrossRef12
Steven E. Lipshultz, William T. Shearer, Bruce Thompson, Kenneth C. Rich, Irene Cheng, E. John Orav, Sulekha Kumar, Ricardo H. Pignatelli, Louis I. Bezold, Philip LaRussa, Thomas J. Starc, Julie S. Glickstein, Sharon O'Brien, Ellen R. Cooper, James D. Wilkinson, Tracie L. Miller, Steven D. Colan. (2011) Cardiac Effects of Antiretroviral Therapy in HIV-Negative Infants Born to HIV-Positive Mothers. Journal of the American College of Cardiology 57:1, 76-85
CrossRef13
Christine J McGrath, Michael H Chung, Barbra A Richardson, Sarah Benki-Nugent, Danson Warui, Grace C John-Stewart. (2011) Younger age at HAART initiation is associated with more rapid growth reconstitution. AIDS 25:3, 345-355
CrossRef14
S Ghosh, J Neubert, T Niehues, O Adams, N Morali-Karzei, A Borkhardt, HJ Laws. (2011) Induction maintenance concept for HAART as initial treatment in HIV infected infants. European Journal of Medical Research 16:6, 243
CrossRef15
Caroline Foster, Sarah Fidler. (2010) Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection. Expert Review of Anti-infective Therapy 8:12, 1403-1416
CrossRef16
Zaheer A Parpia, Robert Elghanian, Arman Nabatiyan, Diana R Hardie, David M Kelso. (2010) p24 Antigen Rapid Test for Diagnosis of Acute Pediatric HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:4, 413-419
CrossRef17
Andres F. Camacho-Gonzalez, Allison C. Ross, Rana Chakraborty. (2010) The Clinical Care of the HIV-1–Infected Infant. Clinics in Perinatology 37:4, 873-885
CrossRef18
Ravindra K. Gupta, Deborah Ford, Veronica Mulenga, A. Sarah Walker, Desire Kabamba, Moxmalama Kalumbi, Paul R. Grant, Alexander Ferrier, Deenan Pillay, Diana M. Gibb, Chifumbe Chintu. (2010) Drug Resistance in Human Immunodeficiency Virus Type-1 Infected Zambian Children Using Adult Fixed Dose Combination Stavudine, Lamivudine, and Nevirapine. The Pediatric Infectious Disease Journal 29:8, e57-e62
CrossRef19
Rosalia Lira, Hilda Valdez-Salazar, Guillermo Vazquez-Rosales, Othon Rojas-Montes, Martha Ruiz-Tachiquin, Rocio Torres-Ibarra, Carlos Cano-Dominguez, Angelica Maldonado-Rodríguez, Alejandro Gomez, Onofre Muñoz, Ma-Teresa Alvarez-Muñoz. (2010) Genotypic testing for HIV-1 drug resistance using dried blood samples. Archives of Virology 155:7, 1117-1125
CrossRef20
Robert W Coombs. 2010. Human Immunodeficiency Viruses: HIV-1 and HIV-2. , 383-400.
CrossRef21
Rohan Hazra, George K. Siberry, Lynne M. Mofenson. (2010) Growing Up with HIV: Children, Adolescents, and Young Adults with Perinatally Acquired HIV Infection*. Annual Review of Medicine 61:1, 169-185
CrossRef22
Annette H Sohn, James JC Nuttall, Fuije Zhang. (2010) Sequencing of antiretroviral therapy in children in low- and middle-income countries. Current Opinion in HIV and AIDS 5:1, 54-60
CrossRef23
Gerardo C. Palacios, Luz M. Sanchez, Evangelina Briones, Teresa J. Ramirez, Hugo Castillo, Lydia G. Rivera, Carlos A. Vazquez, Cristina Rodriguez-Padilla, Mark Holodniy. (2010) Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds. International Journal of Infectious Diseases 14:1, e34-e40
CrossRef24
Jessica Lidström, Qing Li, Donald R Hoover, George Kafulafula, Lynne M Mofenson, Mary G Fowler, Michael C Thigpen, Newton Kumwenda, Taha E Taha, Susan H Eshleman. (2010) Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. AIDS 24:3, 381-386
CrossRef25
Elizabeth Cavalieri, Camila Florido, Élcio Leal, Daisy Maria Machado, Michelle Camargo, Ricardo S. Diaz, Luiz Mario Janini. (2009) Intrahost and Interhost Variability of the HIV Type 1 nef Gene in Brazilian Children. AIDS Research and Human Retroviruses 25:11, 1129-1140
CrossRef26
Amandine Rubio, Fabrice Monpoux, Emilie Huguon, Régine Truchi, Valérie Triolo, Maria-Alessandra Rosenthal-Allieri, Anne Deville, Eric Rosenthal, Patrick Boutté, Albert Tran. (2009) Noninvasive Procedures to Evaluate Liver Involvement in HIV-1 Vertically Infected Children. Journal of Pediatric Gastroenterology and Nutrition 49:5, 599-606
CrossRef27
Elizabeth Maleche Obimbo, Dalton Wamalwa, Barbra Richardson, Dorothy Mbori-Ngacha, Julie Overbaugh, Sandra Emery, Phelgona Otieno, Carey Farquhar, Rose Bosire, Barbara Lohman Payne, Grace John-Stewart. (2009) Pediatric HIV-1 in Kenya: Pattern and Correlates of Viral Load and Association With Mortality. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:2, 209-215
CrossRef28
Ravindra K Gupta, Diana M Gibb, Deenan Pillay. (2009) Management of paediatric HIV-1 resistance. Current Opinion in Infectious Diseases 22:3, 256-263
CrossRef29
Sharon Nichols, John Farley. 2009. HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN CHILDREN. , 269-276.
CrossRef30
Kayvon Modjarrad, Eric Chamot, Sten H Vermund. (2008) Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 22:16, 2179-2185
CrossRef31
François Rouet, Hervé Ménan, Johannes Viljoen, Nicole Ngo-Giang-Huong, Kishor Mandaliya, Diane Valéa, Truong Xuan Lien, Sivapragashini Danaviah, Dominique Rousset, Amandine Ganon, Eric Nerrienet. (2008) In-house HIV-1 RNA real-time RT-PCR assays: principle, available tests and usefulness in developing countries. Expert Review of Molecular Diagnostics 8:5, 635-650
CrossRef32
Elijah Paintsil, Musie Ghebremichael, Sostena Romano, Warren A. Andiman. (2008) Absolute CD4+ T-Lymphocyte Count as a Surrogate Marker of Pediatric Human Immunodeficiency Virus Disease Progression. The Pediatric Infectious Disease Journal 27:7, 629-635
CrossRef33
Samuel B. Foster, Kenneth McIntosh, Bruce Thompson, Ming Lu, Wanrong Yin, Kenneth C. Rich, Hermann Mendez, Leslie K. Serchuck, Clemente Diaz, Mary E. Paul, William T. Shearer. (2008) Increased incidence of asthma in HIV-infected children treated with highly active antiretroviral therapy in the National Institutes of Health Women and Infants Transmission Study. Journal of Allergy and Clinical Immunology 122:1, 159-165
CrossRef34
Jessica D. Church, Wei Huang, Anthony Mwatha, Jonathan Toma, Eric Stawiski, Deborah Donnell, Laura A. Guay, Francis Mmiro, Philippa Musoke, J. Brooks Jackson, Neil Parkin, Susan H. Eshleman. (2008) HIV‐1 Tropism and Survival in Vertically Infected Ugandan Infants. The Journal of Infectious Diseases 197:10, 1382-1388
CrossRef35
Mehri S McKellar, Steven FJ Callens, Robert Colebunders. (2008) Pediatric HIV infection: the state of antiretroviral therapy. Expert Review of Anti-infective Therapy 6:2, 167-180
CrossRef36
K. Patel, M. A. Herna n, P. L. Williams, J. D. Seeger, K. McIntosh, R. B. V. Dyke, G. R. Seage, . (2008) Long-Term Effectiveness of Highly Active Antiretroviral Therapy on the Survival of Children and Adolescents with HIV Infection: A 10-Year Follow-Up Study. Clinical Infectious Diseases 46:4, 507-515
CrossRef37
Bénédicte Danis, Thaddeus C. George, Stanislas Goriely, Binita Dutta, Joëlle Renneson, Laurent Gatto, Patricia Fitzgerald-Bocarsly, Arnaud Marchant, Michel Goldman, Fabienne Willems, Dominique De Wit. (2008) Interferon regulatory factor 7-mediated responses are defective in cord blood plasmacytoid dendritic cells. European Journal of Immunology 38:2, 507-517
CrossRef38
W. M. Sullivan, P. Dorr, M. Perros, R. Hudson, J. Leif, K. Luzuriaga, P. R. Clapham. (2008) Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells. Archives of Virology 153:2, 363-366
CrossRef39
Andrew T. Pavia. 2008. Managing HIV Infection in Children and Adolescents. , 475-485.
CrossRef40
Élcio Leal, Mario Janini, Ricardo S. Diaz. (2007) Selective pressures of human immunodeficiency virus type 1 (HIV-1) during pediatric infection. Infection, Genetics and Evolution 7:6, 694-707
CrossRef41
Katherine Luzuriaga. (2007) Mother-to-child transmission of HIV: A global perspective. Current Infectious Disease Reports 9:6, 511-517
CrossRef42
Elaine J Abrams. (2007) The unanswered question: when to initiate antiretroviral therapy in children with HIV infection. Current Opinion in HIV and AIDS 2:5, 416-425
CrossRef43
Constance Delaugerre, Josiane Warszawski, Marie-Laure Chaix, Florence Veber, Eugenia Macassa, Florence Buseyne, Christine Rouzioux, Stéphane Blanche. (2007) Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children. Journal of Medical Virology 79:9, 1261-1269
CrossRef44
Wendy Mphatswe, Natasha Blanckenberg, Gareth Tudor-Williams, Andrew Prendergast, Christina Thobakgale, Nompumelelo Mkhwanazi, Noel McCarthy, Bruce D Walker, Photini Kiepiela, Philip Goulder. (2007) High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS 21:10, 1253-1261
CrossRef45
NATASCHA CHING, OTTO O. YANG, JAIME G. DEVILLE, KARIN NIELSEN-SAINES, BONNIE J. ANK, MYUNG-SHIN SIM, YVONNE J. BRYSON. (2007) Pediatric HIV-1???Specific Cytotoxic T-Lymphocyte Responses Suggesting Ongoing Viral Replication Despite Combination Antiretroviral Therapy. Pediatric Research PAP,
CrossRef46
Marlyse C Knuchel, Boniphace Jullu, Cyril Shah, Zuzana Tomasik, Marcel P Stoeckle, Roberto F Speck, David Nadal, Hassan Mshinda, J??rg B??ni, Marcel Tanner, J??rg Sch??pbach. (2007) Adaptation of the Ultrasensitive HIV-1 p24 Antigen Assay to Dried Blood Spot Testing. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:3, 247-253
CrossRef47
Takehisa Ikeda, Tong Wei Ch’ng, James M Oleske. (2007) Recommendations in pediatric antiretroviral therapy. Expert Opinion on Pharmacotherapy 8:2, 155-166
CrossRef48
Carlos Alberto Zaccarelli-Filho, Erika Ono, Daisy Maria Machado, Milena Brunialti, Regina Célia de Menezes Succi, Reinaldo Salomão, Esper Georges Kallás, Maria Isabel de Moraes-Pinto. (2007) HIV-1-infected children on HAART: Immunologic features of three different levels of viral suppression. Cytometry Part B: Clinical Cytometry 72B:1, 14-21
CrossRef49
Hannah Green, Diana M Gibb. (2007) Treatment interruption in children with HIV infection. Current Opinion in HIV and AIDS 2:1, 62-68
CrossRef50
Vincent Bekker, Geertje HA Westerlaken, Henriëtte Scherpbier, Sophie Alders, Hans Zaaijer, Debbie van Baarle, Taco Kuijpers. (2006) Varicella vaccination in HIV-1-infected children after immune reconstitution. AIDS 20:18, 2321-2329
CrossRef51
Amy Sarah Ginsburg, Anna Miller, Catherine M. Wilfert. (2006) Diagnosis of Pediatric Human Immunodeficiency Virus Infection in Resource-Constrained Settings. The Pediatric Infectious Disease Journal 25:11, 1057-1064
CrossRef52
Gwenda Verweel, Jesus Saavedra-Lozano, Annemarie M. C. van Rossum, Octavio Ramilo, Ronald de Groot. (2006) Initiating Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Children in Europe and the United States. The Pediatric Infectious Disease Journal 25:11, 987-994
CrossRef53
Howard Minkoff, Lin Shen Xian, D Heather Watts, Robert Leighty, Ron Hershow, Joel Palefsky, Ruth Tuomala, Natalie Neu, Carmen D. Zorrilla, Mary Paul, Howard Strickler. (2006) Relationship of Pregnancy to Human Papillomavirus Among Human Immunodeficiency Virus–Infected Women. Obstetrics & Gynecology 108:4, 953-960
CrossRef54
AK Praharaj. (2006) Problems in diagnosis of HIV infection in babies. Medical Journal Armed Forces India 62:4, 363-366
CrossRef55
Katherine Luzuriaga, Marie-Louise Newell, Francois Dabis, Jean-Louis Excler, John L Sullivan. (2006) Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. The Lancet 368:9534, 511-521
CrossRef56
Katja Doerholt, Trinh Duong, Pat Tookey, Karina Butler, Hermione Lyall, Mike Sharland, Vas Novelli, Andrew Riordan, David Dunn, A Sarah Walker, Diana M. Gibb. (2006) Outcomes for Human Immunodeficiency Virus-1-Infected Infants in the United Kingdom and Republic of Ireland in the Era of Effective Antiretroviral Therapy. The Pediatric Infectious Disease Journal 25:5, 420-426
CrossRef57
Isaac Choge, Tonie Cilliers, Polly Walker, Natasha Taylor, Mary Phoswa, Tammy Meyers, Johannes Viljoen, Avy Violari, Glenda Gray, Penny L. Moore, Maria Papathanosopoulos, Lynn Morris. (2006) Genotypic and Phenotypic Characterization of Viral Isolates from HIV-1 Subtype C-Infected Children with Slow and Rapid Disease Progression. AIDS Research and Human Retroviruses 22:5, 458-465
CrossRef58
R Chakraborty, M Reinis, T Rostron, S Philpott, T Dong, A D'Agostino, R Musoke, E Silva, M Stumpf, B Weiser, H Burger, SL Rowland-Jones. (2006) nef gene sequence variation among HIV-1-infected African children*. HIV Medicine 7:2, 75-84
CrossRef59
Caroline T. Tiemessen, Louise Kuhn. (2006) Immune pathogenesis of pediatric HIV-1 infection. Current HIV/AIDS Reports 3:1, 13-19
CrossRef60
Vincent Bekker, Henriëtte J Scherpbier, Radjin Steingrover, Suzanne Jurriaans, Joep MA Lange, Katja C Wolthers, Taco W Kuijpers. (2006) Viral dynamics after starting first-line HAART in HIV-1-infected children. AIDS 20:4, 517-523
CrossRef61
Yvonne A. Maldonado. 2006. Acquired Immunodeficiency Syndrome in the Infant. , 667-692.
CrossRef62
Jun Yao, Zhen Liu, Lung-Sang Ko, Gang Pan, Yan Jiang. (2005) Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay. Journal of Virological Methods 129:1, 40-46
CrossRef63
Richard M. Rutstein, Kelly A. Gebo, Patricia M. Flynn, John A. Fleishman, Victoria L. Sharp, George K. Siberry, Stephen A. Spector. (2005) Immunologic Function and Virologic Suppression Among Children With Perinatally Acquired HIV Infection on Highly Active Antiretroviral Therapy. Medical Care 43:suppl, III-15-III-22
CrossRef64
E. Seoane Reula, J.M. Bellon, D. Gurbindo, M.A. Munoz-Fernandez. (2005) Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades. British Journal of Dermatology 153:2, 382-389
CrossRef65
Mary E. Paul, Charlotte Mao, Manhattan Charurat, Leslie Serchuck, Marc Foca, Karen Hayani, Edward L. Handelsman, Clemente Diaz, Kenneth McIntosh, William T. Shearer. (2005) Predictors of immunologic long-term nonprogression in HIV-infected children: Implications for initiating therapy. Journal of Allergy and Clinical Immunology 115:4, 848-855
CrossRef66
Albert Faye, Jerôme Le Chenadec, Catherine Dollfus, Isabelle Thuret, Danièle Douard, Ghislaine Firtion, Eric Lachassinne, Martine Levine, Joelle Nicolas, Fabrice Monpoux, Joelle Tricoire, Christine Rouzioux, Marc Tardieu, Marie Jeanne Mayaux, Stéphane Blanche, . (2004) Early versus Deferred Antiretroviral Multidrug Therapy in Infants Infected with HIV Type 1. Clinical Infectious Diseases 39:11, 1692-1698
CrossRef67
Salvador Resino, José Maria Bellón, José Tomás Ramos, Maria Luisa Navarro, Pablo Martín-Fontelos, Esther Cabrero, Maria Ángeles Muñoz-Fernández. (2004) Salvage Lopinavir-Ritonavir Therapy in Human Immunodeficiency Virus-Infected Children. The Pediatric Infectious Disease Journal 23:10, 923-930
CrossRef68
Salvador Resino, José M. Bellón, José Tomas Ramos, Rosa Resino, M. Dolores Gurbindo, M. José Mellado, M. Isabel De José, M. Ángeles Muñoz-Fernández. (2004) Impact of Highly Active Antiretroviral Therapy on CD4 + T Cells and Viral Load of Children with AIDS: A Population-Based Study. AIDS Research and Human Retroviruses 20:9, 927-931
CrossRef69
Louise Kuhn, Elaine J Abrams, Paul Palumbo, Marc Bulterys, Ronnie Aga, Leslie Louie, Thomas Hodge. (2004) Maternal versus paternal inheritance of HLA class I alleles among HIV-infected children. AIDS 18:9, 1281-1289
CrossRef70
Linsay Gray, Mario Cortina-Borja, Marie-Louise Newell. (2004) Modelling HIV-RNA viral load in vertically infected children. Statistics in Medicine 23:5, 769-781
CrossRef71
Daniel L. Tuttle, Carter R. Coberley, Xiaoming Xie, Zhong C. Kou, John W. Sleasman, Maureen M. Goodenow. (2004) Effects of Human Immunodeficiency Virus Type 1 Infection on CCR5 and CXCR4 Coreceptor Expression on CD4 T Lymphocyte Subsets in Infants and Adolescents. AIDS Research and Human Retroviruses 20:3, 305-313
CrossRef72
Susan Givens Bell. (2004) Highly Active Antiretroviral Therapy in Neonates and Young Infants. Neonatal Network: The Journal of Neonatal Nursing 23:2, 55-64
CrossRef73
R. Chandwani, K. A. Jordan, B. L. Shacklett, E. Papasavvas, L. J. Montaner, M. G. Rosenberg, D. F. Nixon, J. K. Sandberg. (2004) Limited Magnitude and Breadth in the HLA-A2-Restricted CD8 T-Cell Response to Nef in Children with Vertically Acquired HIV-1 Infection. Scandinavian Journal of Immunology 59:1, 109-114
CrossRef74
John PA Ioannidis, Athina Tatsioni, Elaine J Abrams, Marc Bulterys, Robert W Coombs, James J Goedert, Bette T Korber, Marie Jeanne Mayaux, Lynne M Mofenson, Jack Moye, Jr, Marie-Louise Newell, David E Shapiro, Jean Paul Teglas, Bruce Thompson, Jeffrey Wiener. (2004) Maternal viral load and rate of disease progression among vertically HIV-1-infected children. AIDS 18:1, 99-108
CrossRef75
(2003) Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. The Lancet 362:9396, 1605-1611
CrossRef76
Elaine J Abrams, Louise Kuhn. (2003) Should treatment be started among all HIV-infected children and then stopped?. The Lancet 362:9396, 1595-1596
CrossRef77
William T. Shearer, Howard M. Rosenblatt, Rebecca S. Gelman, Rebecca Oyomopito, Susan Plaeger, E.Richard Stiehm, Diane W. Wara, Steven D. Douglas, Katherine Luzuriaga, Elizabeth J. McFarland, Ram Yogev, Mobeen H. Rathore, Wende Levy, Bobbie L. Graham, Stephen A. Spector. (2003) Lymphocyte subsets in healthy children from birth through 18 years of age. Journal of Allergy and Clinical Immunology 112:5, 973-980
CrossRef78
Greta R. Bauer, Seth L. Welles, Robert R. Colgrove, Jane Pitt. (2003) Zidovudine Resistance Phenotype and Risk of Perinatal HIV-1 Transmission in Zidovudine Monotherapy???Treated Mothers With Moderately Advanced Disease. JAIDS Journal of Acquired Immune Deficiency Syndromes 34:3, 312-319
CrossRef79
Elaine J Abrams, Jeffrey Wiener, Rosalind Carter, Louise Kuhn, Paul Palumbo, Stephen Nesheim, Francis Lee, Peter Vink, Marc Bulterys. (2003) Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS 17:6, 867-877
CrossRef80
Donald P Kotler. (2003) Human immunodeficiency virus and pregnancy. Gastroenterology Clinics of North America 32:1, 437-448
CrossRef81
Joséphine Braun, Jean-Christophe Plantier, Marie-France Hellot, Edouard Tuaillon, Marie Gueudin, Florence Damond, Anders Malmsten, Gary E Corrigan, François Simon. (2003) A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS 17:3, 331-336
CrossRef82
Steven Nesheim, Paul Palumbo, Kevin Sullivan, Francis Lee, Peter Vink, Elaine Abrams, Marc Bulterys. (2003) Quantitative RNA Testing for Diagnosis of HIV-Infected Infants. JAIDS Journal of Acquired Immune Deficiency Syndromes 32:2, 192-195
CrossRef83
CATHERINE LITALIEN, ALBERT FAYE, ALEXANDRA COMPAGNUCCI, CARLO GIAQUINTO, LYNDA HARPER, DIANA M. GIBB, EVELYNE JACQZ-AIGRAIN. (2003) Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. The Pediatric Infectious Disease Journal 22:1, 48-55
CrossRef84
Jane Mullen, Susan Leech, Siobhan O'Shea, Ian L. Chrystie, Gillian du Mont, Colin Ball, Michael Sharland, Fiona Cottam, Mark Zuckerman, Philip Rice, Philippa Easterbrook, . (2002) Antiretroviral drug resistance among HIV-1 infected children failing treatment. Journal of Medical Virology 68:3, 299-304
CrossRef85
JULIETA KOPKA, MARCELO BATALLA, ANDREA MANGANO, DEBORA MECIKOVSKY, ROSA BOLOGNA, AND, LUISA SEN. (2002) Relevance of Viral Phenotype in the Early AIDS Outcome of Pediatric HIV-1 Primary Infection. Pediatric Research 52:4, 475-480
CrossRef86
E.G Hermione Lyall. (2002) Paediatric HIV in 2002—a treatable and preventable infection. Journal of Clinical Virology 25:2, 107-119
CrossRef87
NICOLE J. COHEN, RONDA ORAM, CHRIS ELSEN, JANET A. ENGLUND. (2002) Response to changes in antiretroviral therapy after genotyping in human immunodeficiency virus-infected children. The Pediatric Infectious Disease Journal 21:7, 647-653
CrossRef88
Saidi H. Kapiga, Heejung Bang, Donna Spiegelman, Gernard I. Msamanga, Jenny Coley, David J. Hunter, Wafaie W. Fawzi. (2002) Correlates of Plasma HIV-1 RNA Viral Load Among HIV-1-Seropositive Women in Dar es Salaam, Tanzania. JAIDS Journal of Acquired Immune Deficiency Syndromes 30:3, 316-323
CrossRef89
Claudia A. Chiriboga. (2002) Human immunodeficiency virus (HIV) in children. Current Treatment Options in Neurology 4:3, 213-224
CrossRef90
M. PERUZZI, C. AZZARI, L. GALLI, A. VIERUCCI, M. DE MARTINO. (2002) Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure. Clinical & Experimental Immunology 128:2, 365-371
CrossRef91
Micheline McCarthy, Jun He, Denise Auger, Rebeca Geffin, Cristina Woodson, Cecelia Hutto, Charles Wood, Gwendolyn Scott. (2002) Cellular tropisms and co-receptor usage of HIV-1 isolates from vertically infected children with neurological abnormalities and rapid disease progression. Journal of Medical Virology 67:1, 1-8
CrossRef92
Jianming Tang, Craig M. Wilson, Margaret Schaen, Angela Myracle, Steven D. Douglas, Richard A. Kaslow. (2002) CCR2 and CCR5 Genotypes in HIV Type 1-Infected Adolescents: Limited Contributions to Variability in Plasma HIV Type 1 RNA Concentration in the Absence of Antiretroviral Therapy. AIDS Research and Human Retroviruses 18:6, 403-412
CrossRef93
Chokechai Rongkavilit, Rolf P. G. van Heeswijk, Sompop Limpongsanurak, Pimolrat Thaithumyanon, Chantana Boonrod, Elly A. M. Hassink, Aeumporn Srigritsanapol, Theshinee Chuenyam, Sasiwimol Ubolyam, Richard M. W. Hoetelmans, Kiat Ruxrungtham, Joep M. A. Lange, David A. Cooper, Praphan Phanuphak. (2002) Dose-Escalating Study of the Safety and Pharmacokinetics of Nelfinavir in HIV-Exposed Neonates. JAIDS Journal of Acquired Immune Deficiency Syndromes 29:5, 455-463
CrossRef94
Luis Gaitán-Cepeda, Juan Morales, Luis Sánchez-Vargas, Sandra Aquino-Garcia, Rodolfo Fragoso-Ríos, Vicente Cuairán-Ruidiaz, Carlos Avila Figueroa. (2002) Prevalence of Oral Lesions in Mexican Children with Perinatally Acquired HIV: Association with Immunologic Status, Viral Load, and Gender. AIDS Patient Care and STDs 16:4, 151-156
CrossRef95
Paul Krogstad, Sophia Lee, George Johnson, Kenneth Stanley, James McNamara, John Moye, J. Brooks Jackson, Rosaura Aguayo, Arry Dieudonne, Margaret Khoury, Hermann Mendez, Sharon Nachman, Andrew Wiznia, . (2002) Nucleoside‐Analogue Reverse‐Transcriptase Inhibitors Plus Nevirapine, Nelfinavir, or Ritonavir for Pretreated Children Infected with Human Immunodeficiency Virus Type 1. Clinical Infectious Diseases 34:7, 991-1001
CrossRef96
RAM YOGEV, SOPHIA LEE, ANDREW WIZNIA, SHARON NACHMAN, KENNETH STANLEY, STEPHEN PELTON, LYNNE MOFENSON, SUSAN FISCUS, ELEANOR JIMENEZ, MOBEEN H. RATHORE, MARY ELIZABETH SMITH, LIN YE SONG, KENNETH MCINTOSH. (2002) Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. The Pediatric Infectious Disease Journal 21:2, 119-125
CrossRef97
Annemarie MC van Rossum, Pieter LA Fraaij, Ronald de Groot. (2002) Efficacy of highly active antiretroviral therapy in HIV-1 infected children. The Lancet Infectious Diseases 2:2, 93-102
CrossRef98
Athena P. Kourtis. (2002) Prevention of Perinatal HIV Transmission. Drugs 62:15, 2213-2220
CrossRef99
Patrick J. Gavin, Ram Yogev. (2002) The Role of Protease Inhibitor Therapy in Children with HIV Infection. Pediatric Drugs 4:9, 581-607
CrossRef100
(2002) Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys?. AIDS 16:1, 97-104
CrossRef101
ALAN MEYERS, AMRIK SHAH, ROBERT H. CLEVELAND, WILLIAM R. CRANLEY, BEVERLY WOOD, SUSAN SUNKLE, SCOTT HUSAK, ELLEN R. COOPER. (2001) Thymic size on chest radiograph and rapid disease progression in human immunodeficiency virus 1-infected children. The Pediatric Infectious Disease Journal 20:12, 1112-1118
CrossRef102
Thomas W. McCloskey, Viraga Haridas, Raj Pahwa, Savita Pahwa. (2001) Human immunodeficiency virus gag and pol-specific CD8 T cells in perinatal HIV infection. Cytometry 46:5, 265-270
CrossRef103
Richard H. Haubrich, Judith S. Currier, Donald N. Forthal, Gildon Beall, Carol A. Kemper, Debra Johnson, Michael P. Dubé, Jimmy Hwang, John M. Leedom, Jeremiah Tilles, J. Allen McCutchan, . (2001) A Randomized Study of the Utility of Human Immunodeficiency Virus RNA Measurement for the Management of Antiretroviral Therapy. Clinical Infectious Diseases 33:7, 1060-1068
CrossRef104
Robert J. Biggar, Robin Broadhead, Michelle Janes, Newton Kumwenda, Taha E. T. Taha, Sharon Cassol. (2001) Viral levels in newborn African infants undergoing primary HIV-1 infection. AIDS 15:10, 1311-1313
CrossRef105
Jaime Deville, Yvonne Bryson. (2001) Perinatal transmission of HIV: Recognition and treatment interventions. Current Infectious Disease Reports 3:4, 388-396
CrossRef106
TRACI BURGESS. (2001) Determinants of Transmission of HIV From Mother to Child. Clinical Obstetrics and Gynecology 44:2, 198-209
CrossRef107
MARGARET KHOURY, ANDREA KOVACS. (2001) Pediatric HIV Infection. Clinical Obstetrics and Gynecology 44:2, 243-275
CrossRef108
F. Salvini, G. Scarlatti, A. Bossi, R. Pinzani, F. Zibordi, C. Giovanettoni, A. Plebani. (2001) Follow-Up of Vertically HIV-1–Infected Long-Surviving Children. AIDS Patient Care and STDs 15:2, 59-65
CrossRef109
(2001) Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 15:3, 309-320
CrossRef110
Susan Maddocks, Dominic Dwyer. (2001) The Role of Non-Nucleoside Reverse Transcriptase Inhibitors in Children with HIV-1 Infection. Paediatric Drugs 3:9, 681-702
CrossRef111
Annemarie Berger, Wolfgang Preiser, Hans Wilhelm Doerr. (2001) The role of viral load determination for the management of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. Journal of Clinical Virology 20:1-2, 23-30
CrossRef112
P. J.R. Goulder, Y. Tang, C. Brander, M. R. Betts, M. Altfeld, K. Annamalai, A. Trocha, S. He, E. S. Rosenberg, G. Ogg, C. A. O'Callaghan, S. A. Kalams, R. E. McKinney, K. Mayer, R. A. Koup, S. I. Pelton, S. K. Burchett, K. McIntosh, B. D. Walker. (2000) Functionally Inert HIV-Specific Cytotoxic T Lymphocytes Do Not Play a Major Role in Chronically Infected Adults and Children. Journal of Experimental Medicine 192:12, 1819-1832
CrossRef113
Rodney J. Y. Ho, Kay Larsen, Tot Bui, Xiao Y. Wang, Arnd M. Herz, Cynthia Sherbert, Eric Finn, Connie Nosbisch, Ann Schmidt, David Anderson, Michael Agy, William R. Morton, Jashvant D. Unadkat. (2000) Suppression of Maternal Virus Load With Zidovudine, Didanosine, and Indinavir Combination Therapy Prevents Mother-to-Fetus HIV Transmission in Macaques. Journal of Acquired Immune Deficiency Syndromes140-149
CrossRef114
Rodney J. Y. Ho, Kay Larsen, Tot Bui, Xiao Y. Wang, Arnd M. Herz, Cynthia Sherbert, Eric Finn, Connie Nosbisch, Ann Schmidt, David Anderson, Michael Agy, William R. Morton, Jashvant D. Unadkat. (2000) Suppression of Maternal Virus Load With Zidovudine, Didanosine, and Indinavir Combination Therapy Prevents Mother-to-Fetus HIV Transmission in Macaques. JAIDS Journal of Acquired Immune Deficiency Syndromes 25:2, 140-149
CrossRef115
RENEE SMITH, KATHLEEN MALEE, MANHATTAN CHARURAT, LARRY MAGDER, CLAUDE MELLINS, CAROL MACMILLAN, JOAN HITTLEMAN, TAMAR LASKY, ANTOLIN LLORENTE, JACK MOYE MD. (2000) Timing of perinatal human immunodeficiency virus type 1 infection and rate of neurodevelopment. The Pediatric Infectious Disease Journal 19:9, 862-871
CrossRef116
Nancy L. Young, Nathan Shaffer, Thongpoon Chaowanachan, Tawee Chotpitayasunondh, Nirun Vanparapar, Philip A. Mock, Naris Waranawat, Kulkanya Chokephaibulkit, Rutt Chuachoowong, Punneeporn Wasinrapee, Timothy D. Mastro, R. J. Simonds. (2000) Early Diagnosis of HIV-1–Infected Infants in Thailand Using RNA and DNA PCR Assays Sensitive to Non-B Subtypes. JAIDS Journal of Acquired Immune Deficiency Syndromes 24:5, 401-407
CrossRef117
Nancy L. Young, Nathan Shaffer, Thongpoon Chaowanachan, Tawee Chotpitayasunondh, Nirun Vanparapar, Philip A. Mock, Naris Waranawat, Kulkanya Chokephaibulkit, Rutt Chuachoowong, Punneeporn Wasinrapee, Timothy D. Mastro, R. J. Simonds. (2000) Early Diagnosis of HIV-1–Infected Infants in Thailand Using RNA and DNA PCR Assays Sensitive to Non-B Subtypes. Journal of Acquired Immune Deficiency Syndromes 24:5, 401-407
CrossRef118
David T. Dunn, RJ Simonds, Marc Bulterys, Leslie A. Kalish, Jack Moye, Andrea de Maria, Christian Kind, Christoph Rudin, Erick Denamur, Anne Krivine, Clive Loveday, Marie-Louise Newell. (2000) Interventions to prevent vertical transmission of HIV-1: effect on viral detection rate in early infant samples. AIDS 14:10, 1421-1428
CrossRef119
Ricardo S. de Souza, Orlando Gómez-Marín, Gwendolyn B. Scott, Silvia Guasti, Mary Jo O'Sullivan, Ricardo Hugo Oliveira, Charles D. Mitchell. (2000) Effect of Prenatal Zidovudine on Disease Progression in Perinatally HIV-1–Infected Infants. JAIDS Journal of Acquired Immune Deficiency Syndromes 24:2, 154-161
CrossRef120
Ricardo S. de Souza, Orlando Gómez-Marín, Gwendolyn B. Scott, Silvia Guasti, Mary Jo O'Sullivan, Ricardo Hugo Oliveira, Charles D. Mitchell. (2000) Effect of Prenatal Zidovudine on Disease Progression in Perinatally HIV-1–Infected Infants. Journal of Acquired Immune Deficiency Syndromes 24:2, 154-161
CrossRef121
JENNIFER S. READ, KENNETH C. RICH, JAMES J. KORELITZ, LYNNE M. MOFENSON, D. ROBERT HARRIS, JOHN H MOYE, WILLIAM A. MEYER, SAVITA G. PAHWA, JAMES W. BETHEL, ROBERT P. NUGENT. (2000) Quantification of human immunodeficiency virus type 1 p24 antigen and antibody rivals human immunodeficiency virus type 1 RNA and CD4+ enumeration for prognosis. The Pediatric Infectious Disease Journal 19:6, 544-551
CrossRef122
M. I. Gaakeer, A. M. C. vanRossum, N. G. Hartwig, R. deGroot. (2000) Toepassing van meervoudige antiretrovirale therapie bij een kind in een vergevorderd stadium van aids. Tijdschrift voor kindergeneeskunde 68:3, 160-165
CrossRef123
Ellen R. Cooper, Manhattan Charurat, David N. Burns, William Blattner, Rodney Hoff. (2000) Brief Report: Trends in Antiretroviral Therapy and Mother-Infant Transmission of HIV. Journal of Acquired Immune Deficiency Syndromes 24:1, 45-47
CrossRef124
Ellen R. Cooper, Manhattan Charurat, David N. Burns, William Blattner, Rodney Hoff. (2000) Brief Report: Trends in Antiretroviral Therapy and Mother-Infant Transmission of HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 24:1, 45-47
CrossRef125
J. C. Palomares, E. J. Perea, E. Terrero, M. J. Torres, M. L. Garcia, J. Romero, A. Alejo. (2000) Detection of resistant mutations in the reverse transcriptase of HIV-1-infected children. Clinical Microbiology and Infection 6:5, 268-270
CrossRef126
Inara Espinelli Souza, M. Lucia Azevedo, Regina C. Succi, Daisy M. Machado, Ricardo S. Diaz. (2000) RNA Viral Load Test for Early Diagnosis of Vertical Transmission of HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 23:4, 358-360
CrossRef127
Inara Espinelli Souza, M. Lucia Azevedo, Regina C. Succi, Daisy M. Machado, Ricardo S. Diaz. (2000) RNA Viral Load Test for Early Diagnosis of Vertical Transmission of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes 23:4, 358-360
CrossRef128
Claire Thorne, Marie-Louise Newell. (2000) Epidemiology of HIV infection in the newborn. Early Human Development 58:1, 1-16
CrossRef129
Deborah Persaud, Theodore Pierson, Christian Ruff, Diana Finzi, Karen R. Chadwick, Joseph B. Margolick, Andrea Ruff, Nancy Hutton, Stuart Ray, Robert F. Siliciano. (2000) A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children. Journal of Clinical Investigation 105:7, 995-1003
CrossRef130
Rosemary Johann-Liang, Sakai E. Lee, Aracelis Fernandez, Joseph Cervia, Gary J. Noel. (2000) Genotypic characterization of human immunodeficiency virus type 1 isolated from vertically infected children with antiretroviral therapy experience. The Pediatric Infectious Disease Journal 19:4, 363
CrossRef131
SALVADOR RESINO, DOLORES GURBINDO, JOSE MARIA BELL?? CANO, SILVIA SANCHEZ-RAM??, ANGELES MU??OZ-FERN??NDEZ. (2000) Predictive Markers of Clinical Outcome in Vertically HIV-1???Infected Infants. A Prospective Longitudinal Study. Pediatric Research 47:4, 509-515
CrossRef132
Martin O. C. Ota, Diarmuid O'Donovan, Abraham S. Alabi, Paul Milligan, Lawrence K. Yamuah, Pa Tamba N'Gom, Elizabeth Harding, Koya Ariyoshi, Andrew Wilkins, Hilton C. Whittle. (2000) Maternal HIV-1 and HIV-2 infection and child survival in The Gambia. AIDS 14:4, 435-439
CrossRef133
Taha E. Taha, Newton I. Kumwenda, Donald R. Hoover, Robert J. Biggar, Robin L. Broadhead, Sharon Cassol, Len van der Hoven, Diane Markakis, George N. Liomba, John D. Chiphangwi, Paolo G. Miotti. (2000) Association of HIV-1 load and CD4 lymphocyte count with mortality among untreated African children over one year of age. AIDS 14:4, 453-459
CrossRef134
Katherine Luzuriaga, John L. Sullivan. (2000) Prevention and Treatment of Pediatric HIV Infection (Contempo 1998: Updates Linking Evidence and Experience). Journal of HIV/AIDS Prevention & Education for Adolescents & Children 3:3, 101-107
CrossRef135
Pier-Angelo Tovo, Maurizio de Martino, Clara Gabiano, Luisa Galli. (2000) Pertussis immunization in HIV-1-infected infants: a model to assess the effects of repeated T cell-dependent antigen administrations on HIV-1 progression.. Vaccine 18:13, 1203-1209
CrossRef136
Donald Brambilla, Patricia S. Reichelderfer, James W. Bremer, David E. Shapiro, Ronald C. Hershow, David A. Katzenstein, Scott M. Hammer, Brooks Jackson, Ann C. Collier, Rhoda S. Sperling, Mary Glenn Fowler, Robert W. Coombs. (1999) The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. AIDS 13:16, 2269-2279
CrossRef137
Mark Holodniy. (1999) Viral load monitoring in HIV Infection. Current Infectious Disease Reports 1:5, 497-503
CrossRef138
DOUGLAS C. WATSON, TERESA L. COLLINS-JONES, SUSAN LOVELACE. (1999) Antiretroviral Therapy of Pediatric HIV Infection: Making Hope a Reality. AIDS Patient Care and STDs 13:10, 587-599
CrossRef139
Garcia, Patricia M., Kalish, Leslie A., Pitt, Jane, Minkoff, Howard, Quinn, Thomas C., Burchett, Sandra K., Kornegay, Janet, Jackson, Brooks, Moye, John, Hanson, Celine, Zorrilla, Carmen, Lew, Judy F., . (1999) Maternal Levels of Plasma Human Immunodeficiency Virus Type 1 RNA and the Risk of Perinatal Transmission. New England Journal of Medicine 341:6, 394-402
Full Text140
Eric S. Daar, Henry Lynn, Sharyne Donfield, Edward Gomperts, Margaret W. Hilgartner, Keith Hoots, David Chernoff, Cheryl Winkler, Stephen J. O'Brien. (1999) Effects of Plasma HIV RNA, CD4+ T Lymphocytes, and the Chemokine Receptors CCR5 and CCR2b on HIV Disease Progression in Hemophiliacs. JAIDS Journal of Acquired Immune Deficiency Syndromes 21:4, 317
CrossRef141
DOUGLAS C. WATSON, JOHN J. FARLEY. (1999) Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. The Pediatric Infectious Disease Journal 18:8, 682-689
CrossRef142
Kovacs, Andrea, Schluchter, Mark, Easley, Kirk, Demmler, Gail, Shearer, William, Russa, Philip La, Pitt, Jane, Cooper, Ellen, Goldfarb, Johanna, Hodes, David, Kattan, Meyer, McIntosh, Kenneth, . (1999) Cytomegalovirus Infection and HIV-1 Disease Progression in Infants Born to HIV-1–Infected Women. New England Journal of Medicine 341:2, 77-84
Full Text143
Paul Krogstad, Christel H. Uittenbogaart, Ruth Dickover, Yvonne J. Bryson, Susan Plaeger, Alan Garfinkel. (1999) Primary HIV Infection of Infants: The Effects of Somatic Growth on Lymphocyte and Virus Dynamics. Clinical Immunology 92:1, 25-33
CrossRef144
George D. McSherry, David E. Shapiro, Robert W. Coombs, Nuala McGrath, Lisa M. Frenkel, Paula Britto, Mary Culnane, Rhoda S. Sperling. (1999) The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076). The Journal of Pediatrics 134:6, 717-724
CrossRef145
MURLI PURSWANI, ROSEMARY JOHANN-LIANG, JOSEPH CERVIA, GARY J. NOEL. (1999) Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: experience with fifty-four perinatally infected children. The Pediatric Infectious Disease Journal 18:6, 512-516
CrossRef146
Duncan Churchill, Jonathan Weber. (1999) Measurement of plasma HIV viral load — Clinical applications. Journal of Infection 38:3, 147-150
CrossRef147
John W. Sleasman, Robert P. Nelson, Maureen M. Goodenow, David Wilfret, Alan Hutson, Michael Baseler, Judy Zuckerman, Philip A. Pizzo, Brigitta U. Mueller. (1999) Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. The Journal of Pediatrics 134:5, 597-606
CrossRef148
(1999) Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. AIDS 13:8, 927-933
CrossRef149
Ann J. Melvin, Allen G. Rodrigo, Kathleen M. Mohan, Paul A. Lewis, Laura Manns-Arcuino, Robert W. Coombs, James I. Mullins, Lisa M. Frenkel. (1999) HIV-1 Dynamics in Children. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20:5, 468-473
CrossRef150
(1999) Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. Acta Paediatrica 88:2, 228-232
CrossRef151
Bharat Parekh, S. Phillips, T.C. Granade, J. Baggs, Dale J. Hu, R. Respess. (1999) Impact of HIV Type 1 Subtype Variation on Viral RNA Quantitation. AIDS Research and Human Retroviruses 15:2, 133-142
CrossRef152
Hulin Wu. (1999) How Frequently Should Viral Load Be Monitored to Evaluate Antiretroviral Therapies in AIDS Clinical Trials?. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20:1, 97-99
CrossRef153
VICKI B. PETERS, LLOYD MAYER, KIRK E. SPERBER. (1999) Correlation of Clinical Parameters and Immunological Function with Human Immunodeficiency Virus Plasma Viremia in Children. Viral Immunology 12:2, 139-148
CrossRef154
Mare Tardien. (1998) HIV-1 and the developing central nervous system. Developmental Medicine & Child Neurology 40:12, 843-846
CrossRef155
F. BUSEYNE, M. BURGARD, J.P. TEGLAS, E. BUI, C. ROUZIOUX, M.-J. MAYAUX, S. BLANCHE, Y. RIVIÈRE. (1998) Early HIV-Specific Cytotoxic T Lymphocytes and Disease Progression in Children Born to HIV-Infected Mothers. AIDS Research and Human Retroviruses 14:16, 1435-1444
CrossRef156
PHILIPPA J. EASTERBROOK, LEWIS K. SCHRAGER. (1998) Workshop Summary : Long-Term Nonprogression in HIV Infection: Methodological Issues and Scientific Priorities Report of an International European Community–National Institutes of Health Workshop, The Royal Society, London, England, November 27–29, 1995. AIDS Research and Human Retroviruses 14:14, 1211-1228
CrossRef157
Rob J. De Boer, Charles A.B. Boucher, Alan S. Perelson. (1998) Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 12:13, 1567-1570
CrossRef158
R J. Simonds, Teresa M. Brown, Donald M. Thea, Sherry L. Orloff, Richard W. Steketee, Francis K. Lee, Paul E. Palumbo, Marcia L. Kalish. (1998) Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants. AIDS 12:12, 1545-1549
CrossRef159
Hsiang Ju Lin, Edward B. Siwak, Ian J. Lauder, F. Blaine Hollinger. (1998) Selection of Appropriate HIV-1 Genomic Regions for Single-Strand Conformation Polymorphism Analysis of the Diversity, Modification, and Transmission of HIV-1 Quasispecies. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 18:5, 409-416
CrossRef160
R Manfredi, P Monari, C Donzelli, G Furlini, MC Re, F Chiodo. (1998) Protease inhibitors in antiviral therapy of paediatric HIV disease. Acta Paediatrica 87:7, 814-816
CrossRef161
Vincent J. Carey, Florence H. Yong, Lisa M. Frenkel, Ross E. McKinney. (1998) Pediatric AIDS prognosis using somatic growth velocity. AIDS 12:11, 1361-1369
CrossRef162
Mark J. Sculpher, Diana Gibb, A E. Ades, Julie Ratcliffe, Trinh Duong. (1998) Modelling the costs of paediatric HIV infection and AIDS. AIDS 12:11, 1371-1380
CrossRef163
Clemente Diaz, Celine Hanson, Ellen R. Cooper, Jennifer S. Read, Jessica Watson, Hermann A. Mendez, Jane Pitt, Kenneth Rich, Vincent Smeriglio, Judy F. Lew. (1998) Disease Progression in a Cohort of Infants With Vertically Acquired HIV Infection Observed From Birth: The Women and Infants Transmission Study (WITS). Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 18:3, 221-228
CrossRef164
UWE WINTERGERST, FLORIAN HOFFMANN, BRIGITTE SÖLDER, GUNDULA NOTHEIS, THEONI PETROPOULOU, JOSEF EBERLE, LUTZ GÜRTLER, BERND H. BELOHRADSKY. (1998) Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus. The Pediatric Infectious Disease Journal 17:6, 495-499
CrossRef165
MAURIZIO DE MARTINO, MARIA ELISABETTA ROSSI, CHIARA AZZARI, MARIA GRAZIA GELLI, LUISA GALLI, ALBERTO VIERUCCI. (1998) Different Meaning of CD38 Molecule Expression on CD4+ and CD8+ Cells of Children Perinatally Infected with Human Immunodeficiency Virus Type 1 Infection Surviving Longer than Five Years. Pediatric Research 43:6, 752-758
CrossRef166
Ellen R. Cooper, Celine Hanson, Clemente Diaz, Hermann Mendez, Rasha Abboud, Robert Nugent, Jane Pitt, Kenneth Rich, Evelyn M. Rodriguez, Vincent Smeriglio. (1998) Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. The Journal of Pediatrics 132:5, 808-812
CrossRef167
S. TETALI, S. BAKSHI, S. THAN, S. PAHWA, E. ABRAMS, J. ROMANO, S.G. PAHWA. (1998) Plasma Virus Load Evaluation in Relation to Disease Progression in HIV-Infected Children. AIDS Research and Human Retroviruses 14:7, 571-577
CrossRef168
Marie-Louise Newell. (1998) Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS 12:8, 831-837
CrossRef169
JENNIFER S. READ, CARL E. FRASCH, KENNETH RICH, GORDON A. FITZGERALD, JOHN D. CLEMENS, JANE PITT, STEPHEN I. PELTON, I. CELINE HANSON, EDWARD HANDELSMAN, CLEMENTE DIAZ, MARY GLENN FOWLER. (1998) The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. The Pediatric Infectious Disease Journal 17:5, 391-397
CrossRef170
(1998) HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. AIDS 12:4, F1???F8
CrossRef171
Donald P. Kotler. (1998) HIV IN PREGNANCY. Gastroenterology Clinics of North America 27:1, 269-280
CrossRef172
MEGAN E. VALENTINE, CYNTHIA R. JACKSON, CINDY VAVRO, CATHERINE M. WILFERT, DANIEL MCCLERNON, MARTY ST. CLAIR, SAMUEL L. KATZ, ROSS E. MCKINNEY. (1998) Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients. The Pediatric Infectious Disease Journal 17:1, 18-23
CrossRef173
(1998) Übersicht. LaboratoriumsMedizin 22:1, 6-13
CrossRef174
C. B. Nourse, K. M. Butler. (1998) Perinatal transmission of hiv and diagnosis of hiv infection in infants: A review. Irish Journal of Medical Science 167:1, 28-32
CrossRef175
V ANDERSON. (1997) THE PLACENTAL BARRIER TO MATERNAL HIV INFECTION. Obstetrics and Gynecology Clinics of North America 24:4, 797-820
CrossRef176
A MELVIN, L FRENKEL. (1997) PEDIATRIC HIV-1 INFECTION. Obstetrics and Gynecology Clinics of North America 24:4, 911-924
CrossRef177
A Krivine, S Le Bourdelles, G Firtion, P Lebon. (1997) Viral kinetics in HIV-1 perinatal infection. The Lancet 350:9076, 493
CrossRef
